Linagliptin-Associated Alopecia and Bullous Pemphigoid by Someili, Ali et al.
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2019_001207 European Journal of Case Reports in Internal Medicine © EFIM 2019
Doi: 10.12890/2019_001207 - European Journal of Case Reports in Internal Medicine - © EFIM 2019
 
Linagliptin-Associated Alopecia and Bullous Pemphigoid
Ali Someili1, Khalid Azzam1, Mohannad Abu Hilal2 
1Department of Medicine, McMaster University, Hamilton, ON, Canada
2Department of Dermatology, McMaster University, Hamilton, ON, Canada
Received: 13/07/2019
Accepted: 31/07/2019
Published: 10/09/2019
How to cite this article: Someili A, Azzam K, Abu Hilal M. Linagliptin-associated alopecia and bullous pemphigoid. EJCRIM 2019;6: 
doi:10.12890/2019_001207.
Conflicts of Interests: The Authors declare that there are no competing interest 
This article is licensed under a Commons Attribution Non-Commercial 4.0 License
ABSTRACT
Bullous pemphigoid is a chronic autoimmune blistering disease. Recently, several reports suggested dipeptidyl peptidase 4 (DPP-4) inhibitors, 
also known as gliptins, were a potential cause of drug-induced bullous pemphigoid but not of both bullous pemphigoid and alopecia areata 
together. Here we describe the case of a 68-year-old man with type 2 diabetes mellitus who developed new onset diffuse alopecia on the 
scalp with diffuse tense bullae over his body a few months after linagliptin was introduced for better control of his diabetes. 
DPP-4 inhibitors are not known to increase the risk of alopecia. To the best of our knowledge, this is the first report of linagliptin-associated 
alopecia areata and bullous pemphigoid, which may help demonstrate if there are any links between DPP-4 inhibitors and alopecia.
LEARNING POINTS
• This is the first report of linagliptin-associated alopecia areata and bullous pemphigoid (BP), which may help demonstrate a link between 
DPP-4 inhibitors and alopecia.
• Since the time of onset of BP after initiation of a DPP-4 inhibitor varies, a high index of suspicion is needed for diagnosis. 
• Early diagnosis is essential as DPP-4 inhibitor withdrawal has a significant effect on disease remission.
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INTRODUCTION
Bullous pemphigoid (BP) is an autoimmune disease where autoantibodies target structural proteins at the dermal–epidermal junction. 
Two hemidesmosomal proteins, 230 kDa protein and 180 kDa antigen, have been identified as the major targets of BP autoantibodies. 
BP manifests with tense blisters on the skin[1]. It is poorly understood although many trigger factors have been identified, such as contrast 
material injection, surgical procedures, mechanical trauma, insect bites, thermal burns, radiotherapy and ultraviolet exposure associated 
with pre-existing psoriasis[2]. Linagliptin is one of the new dipeptidyl peptidase-4 (DPP-4) inhibitors used in the treatment of type 2 diabetes 
mellitus (DM). DPP-4 inhibitors have been recently implicated in inducing BP, but the mechanism is not entirely clear. DPP-4 inhibitors may 
induce anti-basement membrane zone antibodies or other structurally similar antibodies, leading to sub-epidermal bullae and BP[3]. Many 
recent case reports show that use of DPP-4 inhibitors is a risk factor for BP onset, but there is no evidence of an association with alopecia.
CASE DESCRIPTION
A 68-year-old Caucasian man with a complex medical history including type 2 DM presented to the emergency department with a 3–4-week 
history of generalized pruritus, new onset diffuse alopecia and diffuse bullae over his trunk, arms and legs. The patient initially had developed 
bullae and blisters over his legs. Simultaneously, he noticed a significant loss of his scalp and beard hair as well as his eyebrows. This was 
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accompanied by intense pruritus over the abdomen and back for approximately 2 weeks prior to the development of the bullae. The intense 
itching, development of further bullae, and almost complete alopecia prompted the patient to present to the emergency department. 
A review of his history did not reveal any drug allergies and he denied a family history of autoimmune conditions. He had not travelled 
anywhere recently and did not present with any constitutional symptoms or myalgias. His home medications included linagliptin, allopurinol, 
amlodipine, atorvastatin, furosemide, hydralazine, levothyroxine, pantoprazole, rivaroxaban, terazosin and insulin.
His vital signs were all within normal limits: he was afebrile at 36.8°C, his heart rate was 59 bpm, blood pressure was 118/73 mmHg, and 
oxygen saturation was 98% on room air. Physical examination revealed bullae over his back, abdomen and both lower legs and measuring 
approximately 1–3 cm in diameter (Fig. 1). He also had numerous smaller bullae over both flanks, upper arms and lower legs and measuring 
approximately 0.5–1 cm in diameter. There was no specific dermatomal distribution and no oral ulcerations or mucositis. The patient had 
diffuse alopecia on his scalp, eyebrows and beard. There was no erythema, scaling or scarring associated with the hair loss (Fig. 2). 
Figure 2. Diffuse alopecia on the scalp 
and jaw with no erythema, scaling or 
scarring
Investigations 
Initial laboratory investigations revealed an elevated creatinine level of 300 mmol/l (baseline in the mid-200s) with normal electrolytes. The 
patient also had an elevated CRP level of 12.6 mg/l, his white blood cell count was normal at 10.3 g/l, and haemoglobin concentration was 
110 g/l. 
Hospital course 
Skin biopsies performed on admission showed sub-epidermal blisters with multiple eosinophils highly suggestive of BP (Fig. 3). Eosinophils 
are commonly seen in BP, but the diffuse eosinophilia seen in the biopsy specimen raised the possibility of drug-induced BP. Direct 
immunofluorescence showed deposition of IgG and C3 along the basement membrane confirming BP (Fig. 4). Interestingly, linagliptin had 
been introduced a few months before the onset of cutaneous eruptions. At that point, linagliptin was highly suspected as the cause of BP 
and alopecia and therefore was discontinued. The patient was started on prednisone 40 mg with significant improvement of his skin lesions. 
He was then followed by the dermatology department and was started on mycophenolic acid (720 mg by mouth twice a day as a steroid-
sparing agent) and topical clobetasol cream. At his 6-month follow-up, 80–90% of his skin lesions had resolved and his hair had grown back 
(Fig. 5A,B).
 Figure 1. Diffuse tense bullae and blisters on the patient’s initial 
presentation to hospital
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DISCUSSION
BP is not uncommon and has an incidence of 0.2–3/100,000 person-years with a higher incidence in older age groups. A UK study estimated 
the incidence there was 1.4/100,000 person-years[4]. There is a wide variation in mortality rate, with a 1-year mortality rate of 13–41% in 
Europe and 11–23% in the USA[5]. The classic manifestation of BP is diffuse tense blisters, but clinical presentation can also include diffuse 
urticarial or dermatitis plaques [6].
DPP-4 inhibitors are a class of oral hypoglycaemic agents which can be used to treat type 2 DM. DPP-4 inhibitors work by increasing 
glucagon-like peptide-1 and glucose-dependent insulin-trophic polypeptide which leads to increased insulin and inhibits glucagon. Sitagliptin 
was the first agent of this class to be approved by the FDA in 2006[7]. The DPP-4 enzyme has many functions including biological roles in 
pro-inflammatory pathways[8]. DPP-4 is also known as CD26 and is widely expressed in various cell types throughout the body including the 
skin, but the role of the DPP-4 enzyme in autoimmune pathogenesis has not yet been clearly elucidated[9, 10]. A large observational study has 
indicated that the use of DPP-4 inhibitors is associated with an overall 75% increase in the risk of inflammatory bowel disease in patients 
with type 2 DM[9]. However, another large observational study indicated that DPP-4 inhibitor combination therapy appears to be associated 
Figure 3. Sub-epidermal blister with multiple eosinophils 
Figure 4. Direct immunofluorescence revealed deposition of IgG and C3 
along the basement membrane
Figure 5. Almost complete remission of skin lesions 
and alopecia 6 weeks after treatment
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with a decreased risk of autoimmune diseases, including rheumatoid arthritis, compared with non-DPP-4 inhibitor combination therapy[11].
A few months after starting linagliptin, our patient developed alopecia areata totalis and a skin eruption shown to be BP by histological 
examination and immunofluorescence. Several cases of linagliptin-induced BP have been reported (Table 1). However, none of those cases 
described both alopecia areata and BP simultaneously due to linagliptin.
CONCLUSION
This is the first report of linagliptin-associated alopecia areata and BP and may indicate a link between DPP-4 inhibitors and alopecia. 
Although DPP-4 inhibitors are known to be associated with BP, the pathogenesis is still not completely understood. Early diagnosis is 
essential as agent withdrawal has a significant effect on disease remission.
Author Patient age 
and gender
DPP-4i Length of 
time before
 BP onset 
Clinical presentation Treatment Outcome 
Mendonça et al.[12] 82 M Linagliptin 45 Days Pruritic cutaneous eruption. 
No mucosal involvement 
Prednisone taper over 6 months 
and etamethasone-gentamicin 
cream
Followed for 6 months, no further 
exacerbations following linagliptin 
withdrawal
77 F Vildagliptin/
metformin
NA Mucosal involvement at 
onset; afterwards, mucosal 
and cutaneous
Prednisone 1 mg/kg/day Lost to follow-up
72 F Vildagliptin/
metformin
3 Months Pruriginous tense bullae over 
a urticarial base. 
No mucosal involvement 
Prednisone 1 mg/kg/day Followed for >8 months, no further 
exacerbation
Sakai et al.[13] 76 F Linagliptin 9 Months Tense bullae over whole body. 
No mucosal involvement
Topical dexamethasone valerate; 
minocycline 100 mg daily was 
added for a while
Complete remission was achieved at 
16 weeks after the discontinuation 
of linagliptin
Haber et al. [3] 60 M Linagliptin 4 Months Pruritus and erythematous 
tense bullae on the limbs. 
No mucosal involvement
Topical corticosteroid No clinical recurrence of BP during 3 
months of follow-up
70 F Linagliptin 3 Months Pruritus and tense bullae on 
the trunk. 
No mucosal involvement
Topical clobetasol propionate Followed for 5 months with no 
clinical recurrence of BP
García et al. [14] 74 F Vildagliptin/ 
metformin
12 Months Pruritic bullous skin lesions on 
the trunk. 
No mucosal involvement
Oral prednisone for 3 
weeks+topical clobetasol
No clinical recurrence after 3 years 
of follow-up
Yoshiji et al. [15] 81 M Linagliptin 9 Months Erythematous tense bullae 
over entire body. 
No mucosal involvement
20 mg prednisone, then tapered 
off 
Complete remission 6 weeks after 
agent withdrawal
86 M Linagliptin 9 Months Erythematous tense bullae 
over entire body. 
No mucosal involvement
Started on 20 mg/day 
prednisolone, which was tapered 
to 2 mg/day over 10 months
Complete remission 4 weeks after 
agent withdrawal
83 F L i n a g l i p t i n , 
sitagliptin
15 Months Erythematous tense bullae. 
No mucosal involvement
Prednisolone (15 mg/day), then 
replaced by IVIG after 3 days 
because of poor control of BP
Complete remission 2 weeks after 
agent withdrawal
86 F Vildagliptin 6 Months Erythematous tense bullae. 
No mucosal involvement
Started on 40 mg/day 
prednisolone and then received 
IVIG due to poor control of skin 
symptoms
Complete remission 4 weeks after 
agent withdrawal
63 M Anagliptin 5 Months Erythematous bullous 
eruptions over entire body. No 
mucosal involvement
Prednisolone (20 mg/day), 
tapered and stopped within 14 
days 
Complete remission 2 weeks after 
agent withdrawal
Guliani et al. [16] 69 M Teneligliptin/
metformin
4 Months Erythematous, itchy, fluid-
filled lesions. No mucosal 
involvement
Topical clobetasol propionate The skin lesions improved in a 
month. 
Duration of follow-up unknown
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Author Patient age 
and gender
DPP-4i Length of 
time before
 BP onset 
Clinical presentation Treatment Outcome 
Takama et al. [17] 86 F L i n a g l i p t i n , 
anagliptin 
6 Weeks Multiple blisters on both legs.
No mucosal nvolvement
Initially topical clobetasol 
propionate. On day 185, BP 
relapsed so prednisone 7.5 mg 
and mizoribine started
Complete remission on day 220. 
Then no relapses up to day 297
Maki et al. [18] 70 M Teneligliptin 4 Weeks Multiple blisters on the trunk. 
No mucosal involvement
None Followed up for 2 months with no 
clinical recurrence of BP
Harada et al. [19] 78 M Sitagliptin 3 Years Cutaneous blisters on the 
bilateral limbs and abdomen 
Prednisolone 20 mg Died on day 14 
Esposito et al. [20] 73 F Linagliptin 5 Months Diffuse bullous rash IV methylprednisolone (1 mg/kg/
day for 10 days, then tapered) 
and azathioprine (100 mg/day) 
for 12 weeks
Still in remission at 1-year follow-up
Maki et al. [18] 70 M Teneligliptin 4 Weeks Multiple blisters on the trunk. 
No mucosal involvement
None Followed up for 2 months with no 
clinical recurrence of BP
Harada et al. [19] 78 M Sitagliptin 3 Years Cutaneous blisters on the 
bilateral limbs and abdomen 
Prednisolone 20 mg Died on day 14 
Esposito et al. [20] 73 F Linagliptin 5 Months Diffuse bullous rash IV methylprednisolone (1 mg/kg/
day for 10 days, then tapered) 
and azathioprine (100 mg/day) 
for 12 weeks
Still in remission at 1-year follow-up
Keseroglu et al. [21] 61 F Vildagliptin/
metformin
10 Months Pruritic vesiculobullous 
lesions. No mucosal 
involvement
Topical clobetasol Remission within 3 weeks. 
No further follow-up mentioned
Béné et al. [22] 86 F Vildagliptin/
metformin
2 Months Erythematous bullous 
eruption, with bullae on 
healthy skin and extensive 
erosions on the body
Topical clobetasol Condition improved after 
withdrawal of vildagliptin. 
Duration of follow-up not mentioned
79 M Vildagliptin/
metformin
37 Months Generalized erythematous 
vesicular bullous eruption
Topical clobetasol The lesions recurred at 3 months but 
improved after discontinuation of 
vildagliptin. 
The duration of follow-up not 
mentioned
77 F Vildagliptin 26 Months Pruriginous bullous eruption Topical clobetasol Condition improved after 
withdrawal of vildagliptin.
 The duration of follow up not 
mentioned
Aouidad et al. [23] 61 M Vildagliptin/
metformin
5 Months Pruritus and bullous 
haemorrhagic lesions over 
an erythematous base 
disseminated on the trunk and 
the limb
Topical corticosteroid Complete remission 2 weeks after 
agent withdrawal 
Pasmatzi et al. [24] 59 F Vildagliptin/
metformin
2 Months Diffuse bullous eruption 
mostly on an erythematous 
base
0.5 mg/kg/day
methylprednisolone which was 
tapered over 8 weeks
Complete remission 10 weeks after 
agent withdrawal 
67 M Vildagliptin/
metformin
2 Months Diffuse bullous eruption 
mostly on an erythematous 
base
200 mg/day doxycycline 
for 4 weeks
Complete remission 8 weeks after 
agent withdrawal
64 M Linagliptin 6 Months Cutaneous and severe 
mucosal involvement 
0.3 mg/kg/day oral prednisolone Improvement of only cutaneous 
lesions 2 weeks after agent 
withdrawal. 
Mucosal lesions improved 2 weeks 
after starting prednisone. No further 
follow-up
Table 1. Characteristics of previous dipeptidyl peptidase-4 inhibitor (DPP-4i)-induced bullous pemphigoid (BP)
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